HomeAI · summaries
Storia in 3 fonti
Jideytro nabs FDA approval as second-line treatment in non-small cell lung cancer
The FDA has approved zidesamtinib for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer.Zidesamtinib (Jideytro, GSK) is designed to provide highly selective coverage of ROS1 mutations and improved blood-brain-barrier penetration for patients previously treated with a ROS1 kinase inhibitor.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
FDA Greenlights Next-Generation ROS1 Inhibitor for Lung Cancer
Zidesamtinib is indicated for patients who received a prior ROS1 inhibitor
- ·
benzinga.com
FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - GSK (NYSE:GSK)
GSK wins early FDA approval for Jideytro, a targeted treatment for adults with advanced ROS1-positive non-small cell lung cancer.
